Clinical trials: Amlodipine
Healthy
Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers
Study to investigate the effect of food intake on the bioavailability of a fixed dose combination of 80 mg telmisartan / 10 mg amlodipine following a high fat breakfast
- Trial name
- NCT02259777
- Testing
- Telmisartan/Amlodipine, high fat, high caloric meal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Drug-Drug Interaction
Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects
The purpose of this study is to evaluate the Drug interaction and safety of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male volunteers.
- Trial name
- NCT03390465
- Testing
- Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Hypertension
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure…
- Trial name
- NCT00439738
- Testing
- HCTZ + Amlodipine, Valsartan/HCTZ
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Events
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood…
- Trial name
- APOLLO (NCT01259297)
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 185 sites in United States, Argentina and 16 more
- Volunteers
- 2,336 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Volunteers
Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers
Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I
- Trial name
- NCT02058472
- Testing
- G3041, SEVIKAR®
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Healthy
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use
To investigate the bioequivalence of telmisartan administrated in two different ways: both in telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg tablet and amlodipine 5 mg tablets (R) in…
- Trial name
- NCT01344629
- Testing
- Telmisartan/Amlodipin FDC, Telmisartan, Amlodipin
- Where
- Japan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dyslipidemia With Hypertension
Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin
To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.
- Trial name
- NCT03088254
- Testing
- Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
- Where
- 12 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Essential Hypertension
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts.
- Trial name
- NCT02062645
- Testing
- amlodipine/valsartan
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy…
- Trial name
- EXTRA (NCT00666536)
- Testing
- valsartan and amlodipine
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Novartis
Hypertension
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male…
- Trial name
- NCT02548286
- Testing
- Candesartan 8mg, Amlodipine 5mg, CKD-330 8/5mg
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypercholesterolemia
A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period
- Trial name
- NCT00530946
- Testing
- Amlodipine 2.5mg/Atorvastatin 5mg, Amlodipine 2.5mg/Atorvastatin 10mg, Amlodipine 5mg/Atorvastatin 5mg
- Where
- 17 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Metabolic Syndrome
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
A STUDY ON WHETHER AN ANTIHYPERTENSIVE MEDICATION PREVENTS DAMAGE TO WALLS OF VEINS IN FEMALE PATIENTS WITH THE METABOLIC SYNDROME (OVERWEIGHT AND OTHER DISORDERS).
- Trial name
- NCT00241150
- Testing
- VALSARTAN
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension, Dyslipidemias
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive…
- Trial name
- NCT05660135
- Testing
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Essential Hypertension
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension.
- Trial name
- NCT01237873
- Testing
- Ali/Amlo 150/2.5 mg
- Where
- 13 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
This study will assess the safety and efficacy of aliskiren plus hydrochlorothiazide (HCTZ) in patients who do not achieve controlled blood pressure levels after treatment with another specified antihypertensive medication.
- Trial name
- AMAZING (NCT00867490)
- Testing
- Candesartan+HCTZ - Phase 1, Aliskiren+HCTZ - Phase 2, Aliskiren+HCTZ+amlodipine - Phase 3
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Novartis
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical